A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers
Latest Information Update: 22 Apr 2018
Price :
$35 *
At a glance
- Drugs Lapatinib (Primary)
- Indications Biliary cancer; Liver cancer
- Focus Therapeutic Use
- 07 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Oct 2006 Status change
- 22 Aug 2005 New trial record.